Medicine for treating children with congestive splenomegaly
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A congestive, splenomegaly technology, applied in the direction of drug combination, pharmaceutical formula, plant raw materials, etc., can solve the problems of liver cell damage, no benefit of surgical treatment, mild adverse reactions, etc., to relieve portal hypertension, unique formula , delaying the effect of splenomegaly
Inactive Publication Date: 2013-03-27
武英
View PDF4 Cites 4 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
However, the above-mentioned surgical treatment has the following disadvantages: ①The operation requires children to be over 6 years old; ②For the cases of liver cirrhosis, the liver cells have been seriously damaged, and the surgical treatment is not beneficial
Therefore, there is still a lack of a drug that is specially used for children and has mild adverse reactions for the treatment of congestive splenomegaly.
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0028] Example 1, the weight ratio of the raw materials: 6 g of yellow grass, 8 g of bellflower, 8 g of cat's claw, 6 g of weeping grass, 6 g of pangolin, 8 g of red bean, 6 g of anemarrhena, 8 g of Citrus aurantium, 3 g of dried ginger.
Embodiment 2
[0029] Example 2, the weight ratio of the raw materials: 10 g of yellow grass, 15 g of bellflower, 15 g of cat's claw, 10 g of weeping grass, 10 g of pangolin, 15 g of red bean, 10 g of anemarrhena, 15 g of Citrus aurantium, and 6 g of dried ginger.
Embodiment 3
[0030] Example 3, the weight ratio of the raw materials: 8 g of yellow grass, 10 g of bellflower, 10 g of cat's claw, 8 g of weeping grass, 8 g of pangolin, 10 g of red bean, 8 g of anemarrhena, 10 g of Citrus aurantium, 5 g of dried ginger.
[0031] When used, the traditional Chinese medicine of the present invention is decocted twice with water, and the filtrate is combined with the filtrate and taken in the morning and evening. The above-mentioned drug dosage is a single daily dose. Children over 10 years old take the full dose, 5-10 years old take half the dose, and 1 to 5 years old take 1 / 4 dose.
[0032] The effective combination of the above-mentioned drugs and coordination with each other can effectively achieve the purpose of treating congestive splenomegaly in children with fewer side effects. The above results are fully proved by clinical data. The relevant data are as follows. The study drug used is the weight ratio of the raw material in Example 3.
[0033] 1 Objects an...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention discloses a medicine for treating children with congestive splenomegaly, and aims to solve the problem of the treating the children with the congestive splenomegaly. The medicine is characterized by being prepared by adopting multiple plurality of traditional Chinese medicines, and the formula of the raw materials and the weight proportion are as follows: 6 to 10 parts of penthorum chinense pursh, 8 to 15 parts of rust-coloured crotalaria herb with root, 8 to 15 parts of ternate buttercup roots, 6 to 10 parts of sedum sarmentosum, 6 to 10 parts of manis pentadactyla, 8 to 15 parts of phaseolus calcaratus, 6 to 10 parts of rhizoma anemarrhenae, 8 to 15 parts of immature bitter oranges and 3 to 6 parts of rhizoma zingiberis. The clinical experiment proves that the medicine has the characteristics of good treatment effect and higher safety during the treatment of the children with the congestive splenomegaly. Therefore, the medicine is worthy of clinical applications and popularization.
Description
Technical field [0001] The invention relates to the field of traditional Chinese medicine, in particular to a medicine for treating congestive splenomegaly in children. Background technique [0002] Chronic congestive splenomegaly (chronic congestive splenomegaly), also known as portal hypertension (portal hypertension), is a congestive chronic progressive disease of unknown cause. The clinical features are chronic progressive splenomegaly, progressive anemia, white blood cells and platelets Reduction and gastrointestinal bleeding are the main manifestations, and signs of ascites, jaundice, liver dysfunction and liver cirrhosis appear in the late stage. [0003] Chronic congestive splenomegaly is often caused by obstruction of the portal vein due to various reasons. The splenic vein belongs to the portal vein system, and 70% of the blood in the splenic vein of normal people drains into the portal vein. If the portal vein is obstructed, congestive splenomegaly may occur due to blo...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more